3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
2
Phase 2
2
Status
Recruiting
4
Sponsor Class
OTHER
4
INDUSTRY
4
Study Type
Interventional
4
Sponsor
Cancer Type
Tumor-Agnostic
2
Other hematologic neoplasm
2
Lymphoid
2
Genitourinary
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
15
Lung Neoplasms
5
Neoplasms
4
Neoplasm Metastasis
4
Hematologic Neoplasms
3
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Lymphoproliferative Disorders
2
Lymphoma, Large-Cell, Anaplastic
2
Breast Neoplasms
2
Brain Neoplasms
2
Thyroid Neoplasms
1
Sexual Dysfunction, Physiological
1
Sarcoma
1
Rare Tumour
1
Rare Tumor
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroblastoma
1
Lymphoma
1
Glioblastoma
1
Genomic Instability
1
Gastrointestinal Neoplasms
1
Eunuchism
1
Erectile Dysfunction
1
Disease Resistance
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Interventions
Surveys and Questionnaires
114
Exercise
103
Blood Specimen Collection
99
Radiotherapy
67
Gemcitabine
64
Bevacizumab
57
Standard of Care
56
Cisplatin
55
Cyclophosphamide
51
Capecitabine
50
Carboplatin
49
Docetaxel
47
pembrolizumab
46
Dexamethasone
46
Paclitaxel
45
Interviews as Topic
43
Oxaliplatin
40
Magnetic Resonance Spectroscopy
39
Fluorouracil
37
Methods
36
Irinotecan
36
Therapeutics
33
Drug Therapy
33
Radiosurgery
31
Nivolumab
30
Erlotinib Hydrochloride
27
Educational Status
26
Everolimus
24
Leucovorin
23
Control Groups
23
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
OTHER
×
Neoplasms
×
alectinib
×
Clear all
NCT05722886
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
825 enrolled
NCT05770037
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled
NCT04341181
2025-07-25
ProTarget
Rigshospitalet, Denmark
Phase 2
Recruiting
300 enrolled
NCT02925234
2024-01-24
DRUP
The Netherlands Cancer Institute
Phase 2
Recruiting
1,550 enrolled